Hutchison China MediTech Limited Sponsored ADR Stock

$16.36

2.21% yesterday

Nasdaq, Feb 28, 04:46 pm CET

ISIN

US44842L1035

Symbol

HCM

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Hutchison China MediTech Limited Sponsored ADR Stock price

$16.73

-7.21 30.12% 5Y

Nasdaq, Closing price Wed, Feb 26 2025

+0.99 6.29%

ISIN

US44842L1035

Symbol

HCM

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Market capitalization	$2.90b
Enterprise Value	$2.19b
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
EV/Sales (TTM) EV/Sales	3.55
P/S ratio (TTM) P/S ratio	4.70
P/B ratio (TTM) P/B ratio	3.92
Revenue growth (TTM) Revenue growth	-19.35%
Revenue (TTM) Revenue	$617.39m
EBIT (operating result TTM) EBIT	$-122.81m
Free Cash Flow (TTM) Free Cash Flow	$-85.17m
EPS (TTM) EPS	$-0.25
P/E forward	negative
P/S forward	4.41
EV/Sales forward	3.33
Short interest	0.41%

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Get Started for Free Today

Hutchison China MediTech Limited Sponsored ADR Stock Analysis

Unlock Scores for Free

??

18 Analysts have issued a Hutchison China MediTech Limited Sponsored ADR forecast:

17x Buy

94%

More details on Analyst Estimates Including Price Targets

18 Analysts have issued a Hutchison China MediTech Limited Sponsored ADR forecast:

Buy

94%

Hold

Analyst Estimates with Stock Price Targets

Financial data from Hutchison China MediTech Limited Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

TTM Annually

Jun '24		+/- %
Revenue	617 617	19% 19% 100%
- Direct Costs	360 360	7% 7% 58%
Gross Profit	257 257	32% 32% 42%
- Selling and Administrative Expenses	113 113	4% 4% 18%
- Research and Development Expense	256 256	28% 28% 41%
EBITDA	-112 -112	13% 13% -18%
- Depreciation and Amortization	11 11	30% 30% 2%
EBIT (Operating Income) EBIT	-123 -123	15% 15% -20%
Net Profit	-43 -43	18% 18% -7%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Hutchison China MediTech Limited Sponsored ADR Stock News

Neutral

GlobeNewsWire

●

9 days ago

HUTCHMED to Announce 2024 Final Results

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2024 on Wednesday, March 19, 2025 at 7:00 am Eastern Daylight Time (EDT) / 11:00 am Greenwich Mean Time (GMT) / 7:00 pm Hong Kong Time (HKT).

Neutral

GlobeNewsWire

●

about 2 months ago

HUTCHMED Announces NMPA Full Approval for ORPATHYS® (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC

— Indication expands to include treatment-naïve patients — — The 2021 conditional approval in previously treated patients converted to full approval — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 14, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the supplemental New Drug Application for ORPATHYS® (savolitinib) has been gra...

Neutral

GlobeNewsWire

●

about 2 months ago

HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor Therapy

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 02, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application (“NDA”) for the combination of ORPATHYS® (savolitinib) and TAGRISSO® (osimertinib) for the treatment of patients with locally advanced or metastatic epidermal growth factor receptor (“EGFR”) mutation-positi...

More Hutchison China MediTech Limited Sponsored ADR News

Company Profile

Hutchison China MediTech Ltd. is a holding company, which engages in the research and development, manufactures, and sells pharmaceuticals and health oriented consumer products. It operates through the Innovation Platform and Commercial Platform segments. The Innovation Platform segment relates to research and development of innovative therapeutics in oncology and autoimmune diseases. The Commercial Platform segment relates to prescription drugs which develops, manufacture, markets, and sale of prescription pharmaceuticals; and consumer health which comprised of development, manufacture, distribution, and marketing of over-the-counter pharmaceuticals, and consumer health products. The company was founded in June 2000 and is headquartered in Hong Kong.

Head office	Cayman Islands
CEO	Wei Su
Employees	1,988
Founded	2000
Website	www.hutch-med.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now